Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD17137 in Facial Actinic Keratosis
NCT01921907Phase 2
Key facts
- Status
- Completed
- Start
- Jul 2013
- Primary completion
- Jun 2014
- Countries
- 1
- Sponsor
- Assuta Medical Centers
- Modality
- Small Molecules
- Drugs
- AD-17137
- Conditions
- actinic keratosis (AK)
01
Overview
Phase 2, randomised, double-blind trial of AD-17137 in actinic keratosis (AK) (2 arms), sponsored by Assuta Medical Centers. Primary endpoint: Complete Clearance (100% of AK lesions) at 7 weeks. Started Jul 2013; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Active Arm
AD17137 topical treatment for 7 weeks
Placebo Arm
Placebo topical treatment for 4 weeks, followed by AD17137 topical treatment for 3 weeks
03
Who it enrols
Patients aged 30-90 with a clinical diagnosis of Actinic Keratosis and at least 2 clinically diagnosed, 3-15 mm AK lesions on the face or scalp, excluding those with recent specific topical or systemic treatments, hereditary angio-edema, epilepsy, Parkinson's disease, or immunodeficiency disorders.
04
Endpoints
Primary
Complete Clearance (100% of AK lesions)
Secondary
Partial Clearance (75% of AK lesions)
Mean change in lesion size
Change in Investigator Global Assessment
Mean change in lesion number
Change in Patient Global Assessment
Beyond the preview
Go deeper on NCT01921907.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01921907.